At this time, a patent prevents a generic Amturnide (aliskiren-amlodipine-hydrochlorothiazide) from being manufactured in the United States. The first patent is expected to expire in July 2018, which would be the earliest date that a generic version might become available. However, certain circumstances could delay this date, such as lawsuits or other patents for new uses of the drug.
Amturnide is made by Novartis Pharmaceuticals Corporation. It is currently under the protection of a patent that prevents any generic Amturnide from being manufactured in the United States.
When Will a Generic Version Be Available?
The first patent is set to expire in July 2018. This is the earliest predictable date that a generic version could become available. However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for new Amturnide uses. Once the patent expires, there may be several companies that manufacture a generic Amturnide drug.
Are There Generic Versions of the Medications in Amturnide?
Depending on insurance coverage, it may be less expensive to take Amturnide rather than the three medications separately. It may also be more convenient to take one tablet daily, rather than three.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Amturnide [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;2011 April.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. November 10, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click